

Adult E-Poster

treatment options indicated that estrogen-based therapies have demonstrated efficacy in females when initiated before age 11, while the use of testosterone or high-dose estrogen in males remains less well-studied. Given the patient's advanced pubertal status (Tanner stage V) and chronological age, therapy was considered unlikely to be effective. Nevertheless, a shared decision-making process emphasizing supportive management, monitoring, and counseling was undertaken with the patient and his family.

CONCLUSION

The case highlighted the importance of early identification and timely referral for growth-reductive therapy in patients with Marfan Syndrome. Height reduction strategy has been promising, however data is limited with relatively small sample size, with inconclusive evidence on growth-suppressing therapies among male patients.

EP_A119

EXPLORING HYPERGLYCEMIA-RELATED SEIZURES: A CASE SERIES

<https://doi.org/10.15605/jafes.040.S1.127>

Hannah Chen,¹ Sim Sing Yee,^{1,2} Chan Pei Lin,¹
Florence Tan Hui Sieng¹

¹Endocrine Unit, Sarawak General Hospital, Malaysia

²Universiti Malaysia Sarawak (UNIMAS), Malaysia

INTRODUCTION/BACKGROUND

Hyperglycemia-related seizures, though rare, represent a serious complication of uncontrolled diabetes, often occurring in the context of Hyperosmolar Hyperglycaemic State (HHS). We present a retrospective case series detailing the clinical characteristics, metabolic parameters and outcomes of patients admitted with hyperglycemia-related seizures.

CASE

Seven patients (4 females, 3 males) were included, with a median age of 64 years (range 16–76). All except one, a known defaulter, were on insulin therapy. Glycemic control was poor, with a median HbA1c of 9.9% (range 7.4 – 19.8). Random blood glucose levels at presentation ranged from 15 to 48.8 mmol/L. Serum sodium ranged from 120 to 150 mmol/L and serum osmolality ranged from 292.2 to 361.1 mOsm/kg. Three had HHS and one had overlapping diabetic ketoacidosis. Generalised tonic-clonic (GTC) seizures were the most common presentation (n = 6), while one had focal seizures.

Only one patient had a prior history of stroke; none had known epilepsy. Three patients required intubation for airway protection. Potential confounders included

dementia (n = 2), hypertensive crisis (n = 1), liver cirrhosis (n = 2, including one with history of substance abuse) and sepsis (n = 1). Brain CT most commonly showed cerebral atrophy with small vessel disease (n = 4); two had concurrent multifocal infarct. Two EEGs were performed, showing no epileptiform changes. Most patients achieved seizure control following normalization of blood glucose. Three patients were started on antiepileptic medications, and two of these patients were discharged on the same medications. The mortality rate was high, with three deaths occurring during the study period. One of these patients developed a total anterior circulation infarct.

CONCLUSION

Our findings suggest that GTC seizures are more prevalent in patients with severe hyperglycemia. The absence of epileptiform activity on EEG supports a metabolic etiology. Early recognition, aggressive glycemic management and comprehensive post-discharge follow-up are important. These measures may improve neurological outcomes and reduce the high mortality associated with this complication.

EP_A120

PRIMARY ALDOSTERONISM IN PREGNANCY: A CASE REPORT

<https://doi.org/10.15605/jafes.040.S1.128>

Jen Hoong Oon, Noor Hafis Md Tob, Nadiah Noor
Azman, Raja Nurazni Raja Azwan, Zanariah Hussein
Institut Endokrin, Hospital Putrajaya, Putrajaya, Malaysia

INTRODUCTION/BACKGROUND

Primary aldosteronism (PA) in pregnancy is a rare and potentially severe disorder that poses significant challenges for diagnosis and treatment. Compared to essential hypertension, PA is associated with increased risks of preterm delivery, fetal growth restriction, and preeclampsia due to hypertension and hypokalemia.

CASE

We present a 34-year-old primigravida with confirmed PA of ten years duration marked by recurrent episodes of hypokalemia and hypertensive urgency. Despite the initiation of mineralocorticoid receptor antagonist (MRA) treatment, the patient's blood pressure remained poorly controlled, and the patient also had irregular follow-up. She presented at 8 weeks of gestation with uncontrolled hypertension. She required multiple antihypertensive medications with maximal doses as pregnancy progressed, including methyldopa, labetalol, and nifedipine, but BP control remained suboptimal. Imaging revealed a left adrenal nodule, leading to retroperitoneoscopic adrenal-